1 integrin receptor antagonist. Reduces liver metastasis and improves survival in combination with 5-FU
(Cat. No. 3257) in a mouse model of colon cancer. Reduces MLL tumor growth in rats and decreases tumor volume of human MDA-MB-231 cell xenografts in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma.
Livant et al.
Cancer Res., 2000;60:309
A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.
Khalili et al.
Mol.Cancer Ther., 2006;5:2271
Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.
Stoeltzing et al.